Celularity Inc Stock Price, News & Analysis

Celularity Inc. (Nasdaq: CELU) announced the treatment of its first patient with CYNK-101, a genetically modified NK cell therapy, in a Phase 1/2a trial targeting HER2 positive gastric and gastroesophageal junction cancers. The FDA has granted both Fast Track and Orphan Drug Designations, enhancing the trial's potential for expedited review. CYNK-101 aims to synergize with existing antibody therapies, potentially improving survival rates in patients with these difficult-to-treat cancers. The trial's design includes escalating doses to determine safety and efficacy.

Celularity Inc. (Nasdaq: CELU) announced its inclusion in the Russell 3000 and Russell 2000 Indexes, effective June 27, 2022. This milestone follows Celularity's public debut last year and aims to enhance awareness of its placental-derived cell therapies. The Russell Indexes are widely used benchmarks for investment managers, encompassing approximately $12 trillion in assets. Membership signifies a broader market presence for Celularity, which develops innovative therapies targeting cancer and other diseases utilizing unique placental biology.

Celularity Inc. appointed Diane Parks to its Board of Directors, enhancing its expertise in cellular therapies. With over 30 years in the pharmaceutical sector, Parks brings a wealth of experience, having held senior roles at Kite Pharma and Amgen. Her proven track record in launching successful therapies aligns with Celularity's strategic goals. Concurrently, Jay R. Bloom has resigned from the board, marking a significant transition for the company during its growth phase.

Celularity Inc. (Nasdaq: CELU) has announced a definitive agreement with a healthcare-focused investor to sell 4,054,055 shares of its Class A common stock for $7.40 each, raising approximately $30.0 million. The deal includes warrants for an additional 4,054,055 shares at an exercise price of $8.25. The transaction, not involving a public offering, is expected to close around May 20, 2022. Celularity plans to file a registration statement with the SEC to cover the resale of shares issued, enhancing future liquidity for investors.

Celularity Inc. (Nasdaq: CELU) reported financial results for Q1 2022, highlighting a total revenue increase to $5.9 million from $2.7 million in Q1 2021. The firm is advancing its clinical trials for NK cell therapies, including CYNK-001 for acute myeloid leukemia and glioblastoma multiforme, and CYNK-101 for gastric cancer, both of which received FDA designations. R&D expenses rose to $21.7 million, and the company faced a net loss of $62.9 million, improving from $81.5 million a year earlier. Cash and equivalents increased to $48 million as of March 31, 2022.

Celularity Inc. (Nasdaq: CELU) reported significant advancements in its clinical programs for cell therapies, particularly CYNK-001 and CYNK-101, which are in ongoing Phase 1 trials for acute myeloid leukemia and HER2+ gastric cancer, respectively. Both candidates received Fast Track and Orphan Drug Designations from the FDA. The company also highlighted a 46% increase in total revenues to $21.3 million for 2021, although it posted a significant net loss of $100.1 million. Strategic partnerships were formed to expand therapeutic applications, indicating a solid growth trajectory.

Celularity Inc. (Nasdaq: CELU), a clinical-stage biotech firm in Florham Park, N.J., is advancing placental-derived allogeneic cell therapies aimed at cancer and other diseases. On March 17, 2022, at 11:20 AM ET, CEO Robert Hariri and President Andrew Pecora will engage in a fireside chat during the Oppenheimer 32nd Annual Healthcare Conference. This event can be accessed via a live webcast on Celularity’s website, with a replay available for 30 days. Celularity focuses on innovative therapies utilizing natural killer cells and CAR T-cells, addressing global health needs.

Celularity (NASDAQ: CELU) announced that the FDA has granted Orphan Drug Designation for CYNK-101, a genetically modified NK cell therapy aimed at treating advanced HER2/neu positive gastric and gastroesophageal junction cancers. This marks the fifth FDA designation received by Celularity in the last year. CYNK-101 is designed to enhance antibody-dependent cellular cytotoxicity when used with standard therapies like chemotherapy, trastuzumab, and pembrolizumab. The FDA's designation highlights the significant unmet medical need for effective treatments in advanced gastric cancer.

Celularity Inc. (NASDAQ: CELU) has received Fast Track Designation from the FDA for its investigational cell therapy, CYNK-101. This therapy is aimed at treating advanced HER2/neu positive gastric and gastroesophageal junction cancer. The Phase 1/2a trial will assess its safety and efficacy in combination with standard chemotherapy and other agents. Celularity's fast track designation for CYNK-101 marks the third such recognition in less than a year, following similar designations for its other NK cell therapies targeting acute myeloid leukemia and glioblastoma.